Nutrition Business Journal

Alli's Sales Skyrocketing: GSK Looks To Cultivate Distinct Consumer Base, Grow Category, Stay Innovative

NBJ investigates impact of new OTC weight-loss drug on weight-loss supplement category

GlaxoSmithKline’s new OTC weight-loss product alli (orlistat/Xenical 60 mg) is flying off the shelves, gulping in $53 million in sales (excluding Wal-Mart) in the first two months since its June 15, 2007 launch, according to IRI data.

NBJ analysis finds alli contributing greatly to 4 percent growth in total unit sales for the weight-control candy/tablet category during the 12-month period ending Aug. 12, 20

All access premium subscription

This content requires a subscription to Nutrition Business Journal.

As an NBJ subscriber, you receive 10 issues a year and access to the exclusive “NBJ subscriber only” content on (excludes three-month subscriptions), which includes PowerPoint presentations, select data charts and archived articles. Subscribers also receive a 10 percent discount on data charts, comprehensive market research reports and webinars.

Email [email protected] for more information about subscribing.